Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948060

August 20, 2025Open Access

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Methylation-based ctDNA changes predict long-term clinical benefits in patients receiving immune checkpoint inhibitors.
In a real-world pan-cancer study, about 60% of patients experienced significant clinical benefits based on tumor fraction changes.
This observational study analyzed patient data to establish associations between ctDNA levels and treatment effects.
Findings may enable personalized treatment approaches, improving outcomes for cancer patients across diverse types.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Real-world pan-cancer analysis demonstrates that ctDNA tumor fractions predict clinical benefits from immune checkpoint inhibitors, suggesting new prognostic markers.

Abstract

Clinical characteristics of the patients in the evaluable cohort

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc770 https://doi.org/10.1158/2767-9764.29948060

View Full Paper

Ask AI

Bookmark

Share

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers